Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma

Eur J Cancer. 2003 Aug;39(12):1698-703. doi: 10.1016/s0959-8049(03)00382-4.

Abstract

Vascular endothelial growth factor C (VEGF-C) has angiogenic and lymphangiogenic properties and is associated with the development of lymphatic metastases in a number of epithelial malignancies. The aim of this study was to determine VEGF-C protein expression in a series of breast carcinomas and correlate this with axillary lymph node (LN) metastases, the presence of lympho-vascular invasion (LVI), bone marrow micro-metastases (BMM) and other clinico-pathological data including oestrogen receptor (ER) and c-erbB2 status. VEGF-C expression was determined by immunohistochemistry (IHC) in 51 tumours. ER and c-erbB2 were also assessed by IHC. Bone marrow analysis was performed using a combination of immunomagnetic separation and immunocytochemistry. Overall, 30/51 (59%) of the tumours were positive for VEGF-C. There was no significant correlation between VEGF-C expression and LN status, LVI, BMM, tumour size, grade or ER status. However, there was an association between c-erbB2 and VEGF-C expression (P=0.013). The correlation between VEGF-C and c-erbB2 suggests a functional relationship and may, in part, explain the aggressive phenotype associated with c-erbB2-positive tumours.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Marrow Neoplasms / metabolism
  • Bone Marrow Neoplasms / secondary*
  • Breast Neoplasms / metabolism*
  • Endothelial Growth Factors / metabolism*
  • Female
  • Humans
  • Immunohistochemistry / methods
  • Lymphatic Metastasis
  • Middle Aged
  • Neovascularization, Pathologic / metabolism
  • Receptor, ErbB-2 / metabolism*
  • Vascular Endothelial Growth Factor C

Substances

  • Endothelial Growth Factors
  • Vascular Endothelial Growth Factor C
  • Receptor, ErbB-2